Akademik Veri Yönetim Sistemi
Kahramanmaraş Sütçü İmam Üniversitesi Sosyal Bilimler Dergisi, cilt.16, sa.1, ss.117-121, 2021 (Hakemli Dergi)
The incidence of spinal cord astrocytomas (SCAs) is very low and therefore, management of these tumors are challenging due to this paucity. In this report, a patient with a recurrent SCA was successfully treated with bevacizumab after failing to previous therapies including radiotherapy (RT) and temozolomide (TMZ). Bevacizumab is an angiogenesis inhibitor that is widely used in high grade gliomas and shows promise for SCAs spinal cord astrocytomas but there is limited data about the usage of bevacizumab in SCAs. We herein add an important contribution to the literature by reporting a nearly total response to bevacizumab in a patient with low grade SCA.